



December 14, 2022

We are pleased to inform you that today we announced promising preliminary data from the Phase 1/2 MARINA™ study of AOC 1001 in adults with myotonic dystrophy type 1 (DM1).

Treatment with AOC 1001 resulted in meaningful DMPK reduction in 100% of treated participants. Treatment with AOC 1001 also showed splicing improvements and early signs of improvement in myotonia. AOC 1001 was generally well tolerated with most adverse events mild or moderate. You can view our full press release on our corporate website (<https://aviditybiosciences.investorroom.com/news-releases>).

We are also planning to review the preliminary data assessment in a live webinar in partnership with the Myotonic Dystrophy Foundation (MDF) on Friday, December 16th at 9:00am PT (12:00pm ET). You can register to join Friday's webinar on MDF's website (<https://www.myotonic.org/meet-dm-drug-developers>). We hope that you will be able to join us for this planned presentation.

Please note that the preliminary assessment is an early readout from the MARINA trial, and the study continues to be an ongoing, randomized, double-blind, placebo-controlled Phase 1/2 clinical trial. We plan to share additional results from the study next year in 2023.

We continue to work to resolve the partial clinical hold on new participant enrollment as swiftly as possible. The safety of participants in our clinical studies is our top priority. We anticipate sharing an update on the partial clinical hold by the end of the first quarter in 2023. We share the sense of urgency with the DM1 community for effective therapies.

We remain steadfast in our commitment to advance meaningful therapies for the myotonic dystrophy community, and we want to thank each participant in the study, their families, our advocacy partners as well as the investigators and their teams for their time, commitment, and continued contributions.

We encourage you to contact your doctor if you have any questions about AOC 1001, the MARINA trial, or the MARINA-OLE trial.

Sincerely,

The Avidity Team